[Minutes, Advisory Committee to the Director GP-160 Meeting (1992: Bethesda, Maryland)]

19

1 some of the trials that are going on, as well as some
2 background on the product itself, gp-160, as well as
3 then finally discussing some of the deliberations of
4 a vaccine working group which has been established by
5 NIAID for the purpose of evaluating the scientific
6 information for the purpose of the decision making
7 process in making decisions about what products shall
8 go into trials and when they shall go into trials.
9 I think it's a mechanism that you all
10 might be interested in, because it really impacts
11 rather directly on some of the things that we're going
12 to be dealing with today.
13 So without any further ado, I'd like to
14 introduce to you Dr. Daniel Hoth who will discuss the
15 current status of therapeutic HIV vaccine work,
16 focusing on an overview of both completed and ongoing
17 therapeutic vaccine trials. Dan.
18 DR. HOTH: Good afternoon. If I could
19 have the first slide, please.
20 In the next twenty minutes I shall present
21 an overview of therapeutic vaccination in HIV infected
22 individuals.
NEAL R. GROSS
COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVENUE, N.W.
[phone] WASHINGTON, D.C. 20005 [phone]